Drug targets in cancer Flashcards Preview

RACP Oncology 2020 > Drug targets in cancer > Flashcards

Flashcards in Drug targets in cancer Deck (26)
Loading flashcards...
1
Q

3 stages of cell cycle check points

A

G1/S
G2/M
M

2
Q

G1/S check point regulated by

A

retinoblastoma protein

3
Q

G2/M checkpoint regulated by

A

p53 (transcription factor)

4
Q

M checkpoint

A

ensures proper attachment of chromasomes to mitotic spindle. If no proper attachment then cell death

5
Q

Different types of anti-cancer drugs

A

Chemotherapy
ENdocrine therapy
Molecular targeted therapy
Immunotherapy

6
Q

Oncogene addiction

A

When an oncogene uses one signalling transduction pathway.

E.g. HER2 (Breast Ca), BRAF (melanoma) EGFR and ALK (non small cell LC), BCR-ABL (CML)

7
Q

Synthetic lethality

A

loss of function of either 2 or more gene individually has limited effect, but loss of function in both genes leads to cell death

8
Q

Cancer targets can be found by

A

Immunohistochemistry
Insitu hybridisation
Next generation sequencing

9
Q

Re: Molecular targeting agents

what is on target effects?

A
  • side effects that are mechanism based.
  • can be used as clinical biomarkers.
  • e.g. sunitib = HTN
  • gefitinib = rash
10
Q

Re: molecular targeting agents

What is off target effects

A
  • side effect that are caused by inhibition of other targets
  • immune reactions
  • toxic metabolites
  • expression in ormal tissues
  • chemo side effect: mucositis etc
11
Q

What down stream signalling pathway does Tyrosine Kinase use?

A

Ras -> Raf -> MEK -> ERK

and

P13K -> AKt -> mTOR

12
Q

Examples of tyrosine kinase receptors

A

ERBB/HER family
Often gain of function mutation

e.g. ERBB1 = EGFR
ERBB2 = HER2

13
Q

Monoclonal antibodies for EGFR and its side effect

A

Cetuximab and panitumumab

acneiform rash, diarrhoea

14
Q

Examples of TKIs for EGFR

A

Erlotinib, gefitinib (1st generation), afatinib (2nd generation)

side effect: rash, diarrhoea, fatigue, transaminitis.

Treat skin toxicity with: sun protection, oral antibiotics, skin care

15
Q

What is osimertinib?

A

3rd generation EGFR TKI effective against T790M mutation and sensitising mutation.

16
Q

Side effect of osimertinib

A

less skin side effect than 1-2nd line TKIs.

17
Q

Monoclonal antibodies against HER2 in breast ca

A

Trastuzumab and pertuzumab.

side effect: cardiotoxicity

18
Q

Lapatinib

A

Dual EGFR/HER2 TKI

S/E: N/V/D, mucositis, fatigue

19
Q

WHat is Trastuzumab-emtansine?

A

antibody drug conjugate for HER2+ mBC cancer.

S/E: well tolerated, thrombocytopenia/raised aminotransferase

20
Q

Examples of VEGF receptor and multikinase inhibitor

A
"-inib"
Sorafenib
Sunitinib
Pazopanib
Axitinib
Cabozantinib
Lenvatinib
Vandetanib
21
Q

Side effect of multikinase inhibitors

A

VEGF related: HTN, proteinuria, thromboembolism, RPLES

GI, skin, transaminitis/thyroid dysfunction.

22
Q

How do you target Cyclin D/CDK/Rb in the cell cycle as part of cancer treatment?

A

(CDK4/6 + Cyclin D) phosphorylate and inactivate tumour suppressor Rb.

Inhibition of CD4/CD6 leads to reactivation of Rb and cell cycle arrest at G1.

23
Q

What is ribociclib?

A

Selective CD4/6 inhibitor
Given orally w/ aromatase inhibitor.

S/E: neutropenia, LFT derangement, diarrhoea

24
Q

Mechanism of action of PARP inhibitor

A
  • PARP -> repair ss DNA break.
  • ds DNA repair via homologous recombination (BRCA)
  • if PARP is inhibited, then cells rely on homologous recombination to repair cells. If BRCA is mutated, they can’t fix dsDNA break so this leads to cell death.
25
Q

Olaparib

A

PARP inhibitor

TO treat platinum sensitive relapse BRCA+ ovarian, fallopian tube, primary peritoneal cancer.

S/E: nausea, diarrhoea, fatigue

26
Q

Mechanism of drug resistance in cancer

A
  • Primary/intrinsic
  • Secondary via:
    tumour heterogeneity, activation of alternative pathway, alteration of drug target, reactivation of pathway